Recent Updates
Recently added Catalysts
NSPR

InspireMD to Report Second Quarter 2019 Financial Results and Provide Business Update on Tuesday, August 6

Key Takeaway: TEL AVIV, Israel, July 30, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call

Full Press Release Details

TEL AVIV, Israel, July 30, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, August 6, 2019, to discuss financial results for the second quarter and six months ended June 30, 2019, and provide a corporate update.
Conference Call & Webcast: Tuesday, August 6 th @ 8am Eastern Time
Within the US: Outside the US: Conference ID: Webcast: 877-451-6152 201-389-0879 13692587 http://public.viavid.com/index.php?id=135364
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes.
InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
Chief Financial Officer
LifeSci Advisors, LLC
Last updated: Jul 30, 2019